Основы применения совмещенной позитронно-эмиссионной и компьютерной томографии с 18-фтордезоксиглюкозой при дифференцированном раке щитовидной железы после первичного лечения
Аннотация
Благодаря открытию в нашей стране новых центров ядерной медицины для многих пациентов с дифференцированным раком щитовидной железы (ДРЩЖ) стал более доступным не только такой безальтернативный метод лечения, как радиойодтерапия, но и столь же незаменимый в некоторых клинических ситуациях метод обследования, как позитронно-эмиссионная томография, совмещенная с компьютерной томографией (ПЭТ / КТ). Многие годы единственным показанием к применению ПЭТ / КТ при ДРЩЖ считалось подозрение на рецидив опухоли, сопровождающийся повышенным уровнем тиреоглобулина и негативным радиойодсканом. Но за последнее десятилетие показания к применению ПЭТ / КТ при ДРЩЖ значительно расширились. Целью данной обзорной работы является анализ данных литературы, касающихся показаний, преимуществ и ограничений, новых тенденций и рекомендаций относительно применения ПЭТ / КТ при ДРЩЖ.
Об авторах
Т. М. Гелиашвили
ГБУЗ «Челябинский областной клинический онкологический диспансер»
Россия
Россия, 454087 Челябинск, ул. Блюхера, 42
Россия
Россия, 454087 Челябинск, ул. Блюхера, 42
А. В. Важенин
ГБУЗ «Челябинский областной клинический онкологический диспансер»
Россия
Россия, 454087 Челябинск, ул. Блюхера, 42
Россия
Россия, 454087 Челябинск, ул. Блюхера, 42
Н. Г. Афанасьева
ГБУЗ «Челябинский областной клинический онкологический диспансер»
Россия
Россия, 454087 Челябинск, ул. Блюхера, 42
Россия
Россия, 454087 Челябинск, ул. Блюхера, 42
Список литературы
1. Чиссов В.И., Дарьялова С.Л. Онкология. М.: ГЭОТАР-Медиа, 2007. [Chissov V.I., Daryalova S.L. Oncology. Moscow: GEOTAR-Media, 2007. (In Russ.)].
2. Злокачественные новообразования в России в 2013 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2015. [Malignant neoplasms in Russia in 2013 (morbidity and mortality). Eds. A.D. Kaprin, V.V. Starinsky, G.V. Petrova.Moscow, 2015. (In Russ.)].
3. Sherman S.I. Thyroid carcinoma. Lancet 2003;361(9356):501–11. DOI: 10.1016/S0140- 6736(03)12488-9. PMID: 12583960
4. Sipos J.A., Mazzaferri E.L. Thyroid Cancer Epidemiology and Prognostic Variables. Clin Oncol (R Coll Radiol) 2010;22(6):395–404. DOI: 10.1016/j.clon.2010.05.004. PMID: 20627675
5. Eustatia-Rutten C.F., Corssmit E.P., Biermasz N.R. et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006;91(1):313–9. DOI: 10.1210/jc.2005-1322. PMID: 16263822
6. Davies L., Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973– 2002. JAMA 2006;295(18):2164–7. DOI: 10.1001/jama.295.18.2164. PMID: 16684987
7. Schonberger J., Ruschoff J., Grimm D. et al. Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study. Thyroid 2002;12(9):747–54. DOI: 10.1089/105072502760339307. PMID: 12481939
8. Grabellus F., Nagarajah J., Bockisch A. et al. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med 2012;37(2):121–7. DOI: 10.1097/RLU.0b013e3182393599. PMID: 22228332
9. Bongiovanni M., Paone G., Ceriani L. et al. Cellular and molecular basis for thyroid cancer imaging in nuclear medicine. Clin Transl Im 2013;1(3):149–61. DOI: 10.1007/s40336-013-0025-z.
10. Заплатников К., Менцель К., Диль М. и др. Позитронно-эмиссионная томография с 18F-фтордезоксиглюкозой в ракурсе современной диагностики, диспансерного наблюдения и лечения дифференцированного рака щитовидной железы. Проблемы эндокринологии 2004;(1–2):46–50. [Zaplatnikov K., Mentsel’ K., Dil’ M. et al. Positron emission tomography with 18F-fluorodepxyglucose in current diagnostics, out-patient observation, and treatment of thyroid cancer. Problems of Endocrinology 2004; (1–2):46–50. (In Russ.)].
11. Wadsak W., Mitterhauser M. Basics and principles of radiopharmaceuticals for PET/CT. Eur J Radiol 2010;73(3):461–9. DOI: 10.1016/j.ejrad.2009.12.022. PMID: 20181453
12. Joensuu H., Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med 1987;28(5):910–4. PMID: 3572549.
13. Feine U., Lietzenmayer R., Hanke J.P. et al. Fluorine-18-FDG and iodine-131- iodide uptake in thyroid cancer. J Nucl Med 1996;37(9):1468–72. PMID: 8790195
14. Seo Y.L., Yoon D.Y., Baek S. et al. Detection of neck recurrence in patients with differentiated thyroid cancer: comparison of ultrasound, contrastenhanced CT and (18)F- FDG PET/CT using surgical pathology as a reference standard: (ultrasound vs. CT vs. (18) F- FDG PET/CT in recurrent thyroid cancer). Eur Radiol 2012;22(10):2246–54. DOI: 10.1007/s00330-012-2470-x. PMID: 22562091
15. Seo J.H., Lee S.W., Ahn B.C., Lee J. Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG PET/CT. Clin Endocrinol (Oxf) 2010;72(4):558–63. DOI: 10.1111/j.1365- 2265.2009.03693.x. PMID: 19744107
16. Hall N.C., Kloos R.T. PET imaging in differentiated thyroid cancer: where does it fit and how do we use it? Arq Bras Endocrinol Metabol 2007;51(5):793–805. DOI: 10.1590/S0004- 27302007000500017. PMID: 17891243
17. O’Neill C.J., Oucharek J., Learoyd D., Sidhu S.B. Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist 2010;15(2):146–56. DOI: 10.1634/theoncologist.2009-0190. PMID: 20142332
18. Durante C., Haddy N., Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91(8):2892–9. DOI: 10.1210/jc.2005-2838. PMID: 16684830
19. Валдина Е.А. Заболевания щитовидной железы: Руководство. СПб.: Питер, 2006. [Valdina E.A. Thyroid disorders. Guidelines. Saint-Petersburg: Piter, 2006. (In Russ.)].
20. Schlumberger M.J. Diagnostic follow-up of well-differentiated thyroid carcinoma: Historical perspective and current status. J Endocrinol Invest 1999;22(11 suppl): 3–7. PMID: 10726999
21. Casara D., Rubello D., Saladini G. et al. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate analysis of prognostic variables. J Nucl Med 1993;34(10):1626–31. PMID: 8410272
22. Schlumberger M.J., Arcangioli O., Piekarski J.D. et al. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med 1988;29(11):1790–4. PMID: 3183748
23. King A.D. Imaging for staging and management of thyroid cancer. Cancer Imaging 2008;8:57–69. DOI: 10.1102/1470-7330.2008.0007. PMID: 18390389
24. Kucuk O.N., Gultekin S.S., Aras G., Ibis E. Radioiodine whole-body scans, thyroglobulin levels, 99mTc-MIBI scans and computed tomography: results in patients with lung metastases from differentiated thyroid cancer. Nucl Med Commun 2006;27(3):261–6. PMID: 16479246
25. Dietlein M., Scheidhauer K., Voth E. et al. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997;24(11):1342–8. PMID: 9371865
26. Salvatori M., Biondi B., Rufini V. Imaging in endocrinology: 2-[18F]-fluoro-2- deoxy-D- glucose positron emission tomography/computed tomography in differentiated thyroid carcinoma: clinical indications and controversies in diagnosis and follow-up. Eur J Endocrinol 2015;173(3):R115–30. DOI: 10.1530/EJE-15-0066. PMID: 25947140
27. Leboulleux S., Schroeder P.R., Busaidy N.L. et al. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab 2009;94(4):1310–6. DOI: 10.1210/jc.2008-1747. PMID: 19158200
28. Padovani R.P., Robenshtok E., Brokhin M., Tuttle R.M. Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer. Thyroid 2012;22(8):778–83. DOI: 10.1089/thy.2011.0522. PMID: 22780333
29. Tuttle R.M., Tala H., Shah J. et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 2010;20(12):1341–9. DOI: 10.1089/thy.2010.0178.
30. Cooper D.S., Doherty G.M., Haugen B.R. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19(11):1167–214. DOI: 10.1089/thy.2009.0110. PMID: 19860577
31. Treglia G., Bertagna F., Piccardo A., Giovanella L. 131-I- whole-body scan or 18-FDG- PET/CT for patients with elevated thyroglobulin and negative ultrasound? Clin Translat Im 2013;1(3):175–83. DOI: 10.1007/s40336-013-0024-0.
32. Leboulleux S., El Bez I., Borget I. et al. Postradioiodine treatment whole body scan in the era of fluorodesoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels. Thyroid 2012;22(8):832–8. DOI: 10.1089/thy.2012.0081.
33. Dong M.J., Liu Z.F., Zhao K. et al. Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan. Meta-analysis. Nucl Med Commun 2009;30(8):639–50. DOI: 10.1097/MNM.0b013e32832dcfa7. PMID: 19512954
34. Kim W.G., Ryu J.S., Kim E.Y. et al. Empiric high-dose 131-Iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18-F-Fluorodeoxyglucose positron emission tomography scan. J Clin Endocrinol Metab 2010;95(3):1169–73. DOI: 10.1210/jc.2009-1567.
35. Giovanella L. Positron emission tomography/computed tomography in patients treated for differentiated thyroid carcinomas. Exp Rev Endocrinol Metab 2012;7(1):35–43. DOI: 10.1586/eem.11.83.
36. Pacak K., Eisenhofer G., Goldstein D.S. Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev 2004;25(4):568–80. DOI: 10.1210/er.2003-0032. PMID: 15294882
37. Robbins R.J., Wan Q., Grewal R.K. et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2- deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006;91(2):498–505. DOI: 10.1210/jc.2005-1534. PMID: 16303836
38. Deandreis D., Al Ghuzlan A., Leboulleux S. et al. Do histological, immunohistochemical and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome? Endocr Relat Cancer 2011;18(1):159–69. DOI: 10.1677/ERC-10-0233.
39. Wang W., Larson S.M., Fazzari M. et al. Prognostic value of [18F] fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocr Metab 2000;85(3):1107–13. DOI: 10.1210/jcem.85.3.6458. PMID: 10720047
40. Pryma D.A., Schoder H., Gonen M. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients. J Nucl Med 2006;47(8):1260–6. PMID: 16883003
41. Rosenbaum-Krumme S.J., Gorges R., Bockisch A., Binse I. 18F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. Eur J Nucl Med Mol Imaging 2012;39(9):1373–80. DOI: 10.1007/s00259-012-2065-4. PMID: 22718304
42. Gaertner F.C., Okamoto S., Shiga T. et al. FDG PET performed at thyroid remnant ablation has a higher predictive value for long-term survival of high-risk patients with well- differentiated thyroid cancer than radioiodine uptake. Clin Nucl Med 2015;40(5):378–83. DOI: 10.1097/RLU.0000000000000699. PMID: 25608175
43. Sisson J.C., Ackermann R.J., Meyer M.A., Wahl R.L. Uptake of 18-fluoro-2-deoxy- D- glucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrinol Metab 1993;77(4):1090–4. DOI: 10.1210/jcem.77.4.8408458. PMID: 8408458
44. van Tol K.M., Jager P.L., Piers D.A. et al. Better yield of (18)fluorodeoxyglucosepositron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid 2002;12(5):381–7. DOI: 10.1089/105072502760043459. PMID: 12097198
45. Grunwald F., Biersack H.J. FDG PET in thyroid cancer: thyroxine or not? J Nucl Med 2000;41(12):1996–8. PMID: 11138684
46. Marcus C., Whitworth P.W., Surasi D.S. et al. PET/CT in the management of thyroid cancers. AJR Am J Roentgenol 2014;202(6):1316–29. DOI: 10.2214/AJR.13.11673.
47. Vural G.U., Akkas B.E., Ercakmak N. et al. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data. Clin Nucl Med 2012;37:953–9. DOI: 10.1097/RLU.0b013e31825b2057. PMID: 22899202
48. Zoller M., Kohlfuerst S., Igerc I. et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality? Eur J Nucl Med Mol Imaging 2007;34(4):487–95. DOI: 10.1007/s00259-006-0276-2. PMID: 17103166
49. Bertagna F., Bosio G., Biasiotto G. et al. F-18 FDGPET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level. Clin Nucl Med 2009; 34:756–61. DOI: 10.1097/RLU.0b013e3181b7d95c. PMID: 19851169
50. Schluter B., Bohuslavizki K.H., Beyer W. et al. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 2001;42(1):71–6. PMID: 11197983
51. Shammas A., Degirmenci B., Mountz J.M. et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic welldifferentiated thyroid cancer. J Nucl Med 2007;48(2):221–6. PMID: 17268018
52. Bertagna F., Biasiotto G., Orlando E. et al. Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients affected by differentiated thyroid carcinoma, high thyroglobulin level, and negative 131I scan: review of the literature. Jpn J Radiol 2010;28(9):629–36. DOI: 10.1007/s11604-010-0488-z.
53. Zimmer L.A., McCook B., Meltzer C. et al. Combined positron emission tomography/computed tomography imaging of recurrent thyroid cancer. Otolaryngol Head Neck Surg 2003;128(2):178–84. DOI: 10.1067/mhn.2003.74. PMID: 12601311
54. Giovanella L., Trimboli P., Verburg F.A. et al. Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2013;40(6):874–80. DOI: 10.1007/s00259-013-2370-6. PMID: 2346330
55. Nanni C., Rubello D., Fanti S. et al. Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer. Biomed Pharmacother 2006;60(8):409–13. DOI: 10.1016/j.biopha.2006.07.008. PMID: 16891093
56. Palmedo H., Bucerius J., Joe A. et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 2006;47(4):616–24. PMID: 16595495
Для цитирования:
Гелиашвили Т.М., Важенин А.В., Афанасьева Н.Г. Основы применения совмещенной позитронно-эмиссионной и компьютерной томографии с 18-фтордезоксиглюкозой при дифференцированном раке щитовидной железы после первичного лечения. Опухоли головы и шеи. 2017;7(1):12-21. https://doi.org/10.17650/2222-1468-2017-7-1-12-21
For citation:
Geliashvili T.M., Vazhenin A.V., Afanas’eva N.G. The use of 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography in patients with differentiated thyroid cancer after initial treatment. Head and Neck Tumors (HNT). 2017;7(1):12-21. (In Russ.) https://doi.org/10.17650/2222-1468-2017-7-1-12-21
Просмотров: 2423
Послать статью по эл. почте 